Dr. Levin joined RA Capital Management in 2015, is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Andrew holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.